These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
99 related articles for article (PubMed ID: 23891611)
1. Do therapeutic bile acids hit the sweet spot of glucose metabolism in NAFLD? Karpen SJ Gastroenterology; 2013 Sep; 145(3):508-10. PubMed ID: 23891611 [No Abstract] [Full Text] [Related]
2. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Mudaliar S; Henry RR; Sanyal AJ; Morrow L; Marschall HU; Kipnes M; Adorini L; Sciacca CI; Clopton P; Castelloe E; Dillon P; Pruzanski M; Shapiro D Gastroenterology; 2013 Sep; 145(3):574-82.e1. PubMed ID: 23727264 [TBL] [Abstract][Full Text] [Related]
3. Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis. Adorini L; Pruzanski M; Shapiro D Drug Discov Today; 2012 Sep; 17(17-18):988-97. PubMed ID: 22652341 [TBL] [Abstract][Full Text] [Related]
4. Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease. Sanyal AJ Dig Dis; 2015; 33(3):426-32. PubMed ID: 26045279 [TBL] [Abstract][Full Text] [Related]
6. Nuclear receptors: how do they position in non-alcoholic fatty liver disease treatment? Machado MV; Cortez-Pinto H Liver Int; 2014 Oct; 34(9):1291-4. PubMed ID: 24766162 [No Abstract] [Full Text] [Related]
7. NAFLD: obeticholic acid for the treatment of fatty liver disease--NASH no more? Ray K Nat Rev Gastroenterol Hepatol; 2015 Jan; 12(1):1. PubMed ID: 25421586 [No Abstract] [Full Text] [Related]
8. Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost. Musso G Hepatology; 2015 Jun; 61(6):2104-6. PubMed ID: 25753820 [No Abstract] [Full Text] [Related]
9. Farnesoid X receptor agonist for the treatment of liver and metabolic disorders: focus on 6-ethyl-CDCA. Fiorucci S; Cipriani S; Mencarelli A; Baldelli F; Bifulco G; Zampella A Mini Rev Med Chem; 2011 Aug; 11(9):753-62. PubMed ID: 21707532 [TBL] [Abstract][Full Text] [Related]
10. Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease. Makri E; Cholongitas E; Tziomalos K World J Gastroenterol; 2016 Nov; 22(41):9039-9043. PubMed ID: 27895393 [TBL] [Abstract][Full Text] [Related]
11. Current treatment options for nonalcoholic fatty liver disease. Shetty A; Syn WK Curr Opin Gastroenterol; 2019 May; 35(3):168-176. PubMed ID: 30844893 [TBL] [Abstract][Full Text] [Related]
12. Current and upcoming pharmacotherapy for non-alcoholic fatty liver disease. Rotman Y; Sanyal AJ Gut; 2017 Jan; 66(1):180-190. PubMed ID: 27646933 [TBL] [Abstract][Full Text] [Related]
13. FXR Agonists: From Bench to Bedside, a Guide for Clinicians. Alawad AS; Levy C Dig Dis Sci; 2016 Dec; 61(12):3395-3404. PubMed ID: 27734248 [No Abstract] [Full Text] [Related]
14. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. Golabi P; Bush H; Younossi ZM Clin Liver Dis; 2017 Nov; 21(4):739-753. PubMed ID: 28987260 [TBL] [Abstract][Full Text] [Related]
15. The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives. Gitto S; Guarneri V; Sartini A; Andreone P Expert Rev Gastroenterol Hepatol; 2018 Feb; 12(2):165-171. PubMed ID: 29082798 [TBL] [Abstract][Full Text] [Related]